• Molecular NamePhysostigmine
  • SynonymErserine; Eserine; Eserine Salicylate; Eserine Sulfate; Eserolein, Methylcarbamate; Isopto Eserine
  • Weight261.325
  • Drugbank_IDDB00981
  • ACS_NO57-47-6
  • Show 2D model
  • LogP (experiment)1.58
  • LogP (predicted, AB/LogP v2.0)1.82
  • pka1.8, 7.9 (25°)
  • LogD (pH=7, predicted)0.78
  • Solubility (experiment)13.3 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-0.68
  • LogSw (predicted, AB/LogsW2.0)2.36
  • Sw (mg/ml) (predicted, ACD/Labs)5.12
  • No.of HBond Donors1
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds2
  • TPSA44.81
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA parasympathomimetic, specifically, a reversible cholinesterase inhibitor alkaloid of the Calabar bean.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability10.0
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMajor metabolite: Eseroline
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySide effects include increased sweating, loss of bladder control, muscle weakness, nausea, vomiting, diarrhea, or stomach cramps or pain, shortness of breath, tightness in chest, or wheezing, slow or irregular heartbeat, unusual tiredness or weakness, watering of mouth, blurred vision or change in near or distant vision, and eye pain.
  • LD50 (rat)N/A
  • LD50 (mouse)LD50=4.5 (ip)